The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol.
Gulsah AlbayrakFunda Demirtas KorkmazDuygu TozcuIrem Dogan TuracliPublished in: Journal of cellular biochemistry (2019)
Elesclomol might provide an alternative treatment approach for patients with KRAS mutant lung adenocarcinoma and other solid tumor malignancies that harbor KRAS mutations. This would enable the development of biomarker-driven targeted therapy for KRAS mutant adenocarcinoma patients.
Keyphrases
- wild type
- end stage renal disease
- ejection fraction
- chronic kidney disease
- induced apoptosis
- newly diagnosed
- prognostic factors
- type diabetes
- cell cycle arrest
- cancer therapy
- metabolic syndrome
- patient reported outcomes
- drug delivery
- oxidative stress
- combination therapy
- cell proliferation
- rectal cancer
- smoking cessation